- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Complaint about omission of prescribing information/obligatory information. PMCPA concluded no breach and that the matter was outwith the scope of the ABPI…
Complaint about promotion of Brintellix. PMCPA recorded no breach because the matter was outwith the scope of the ABPI Code. No case…
Anonymous complaint about Lilly meeting sponsorship. PMCPA concluded the matter was outwith the scope of the ABPI Code (2012). No breach and…
AstraZeneca challenged a GSK leavepiece on the CONCEPT asthma study. The Panel ruled it misleading for omitting key context on average doses…
An Arimidex mailing used an envelope printed “Happy Birthday” with candles and no company identifiers. The PMCPA ruled it gave a misleading…
A Champix GP referral letter pad used by smoking cessation advisers/pharmacists was handed to patients to take to GPs. PMCPA found exaggerated…
A PCT medicines management lead challenged a Glucophage SR journal ad. PMCPA ruled the ‘More GI-friendly than IR metformin!’ headline was misleading/unsubstantiated…
Media and GP complaints alleged GSK-sponsored nurse audits and bonuses were designed to influence prescribing. PMCPA found the services enhanced patient care,…
A pharmacist challenged Pfizer quotes in a Times article about switching to generic statins. The Panel assessed Pfizer’s briefing to the journalist…
Feraccru HCP website FAQs were challenged. Hb/CKD wording was not a breach, but pregnancy/breastfeeding FAQ omitted the SPC precaution to avoid use,…
PMCPA case AUTH/2401/4/11 (Anonymous v Meda) about promotion of Rhinolast. The matter was ruled outwith the scope of the ABPI Code; no…
Complaint alleged inappropriate lunch hospitality and pre-licence promotion/uncertified slides for unlicensed Epidiolex. Panel found complainant hadn’t proved breaches; unsolicited request exemption applied.…
Janssen admitted a Zytiga journal ad ran in Sept and Oct 2018 with superseded prescribing information. Despite third-party errors, the PMCPA held…
PMCPA Director complaint about clinical trial disclosure for Lyxumia and Zaltrap. Outcome: No breach and deemed outwith the scope of the Code…
Two Shionogi Europe LinkedIn posts celebrating Fetcroja’s CHMP update and marketing authorisation were ruled pre-licence promotion and, once authorised, promotion of a…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.